ABSTRACT 9071
Brigatinib in ALK+ crizotinib-refractory non–small cell lung cancer (NSCLC): Final results of the
Phase 1/2 and ALTA trials
POSTER SESSION
Lung Cancer - Non-Small
Cell Metastatic
https://meetinglibrary.asco.org/record/200517/abstract
ABSTRACT 9042
Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung
cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort
POSTER SESSION
Lung Cancer - Non-Small
Cell Metastatic
https://meetinglibrary.asco.org/record/200468/abstract
C-ANPROM/TW/BRI/0008 Jun2021